Anthropic, the company behind Claude, is pushing its AI further into drug discovery. It has partnered with six firms, including Bristol Myers Squibb, to speed up several stages of making medicines.
Generate Biomedicines is adapting CAR T-cell therapy, usually used on blood cancers, for solid tumours, and a redesigned genetic section it drafted with Claude Code helped immune cells make roughly 10 times more receptors in lab tests.
Much of this work is still preclinical, though one muscular dystrophy candidate could enter human trials as early as late 2028 if early results hold up.
Anthropic, the maker of the Claude AI models, has kicked off its IPO roadshow and is looking to raise as much as $64.35 billion. It plans to sell 825 million shares at an expected $70 to $78 each, listing on Nasdaq as ANT.
Anthropic itself is issuing most of the shares, while existing shareholders are selling the rest.
Its filing shows first-half 2026 revenue of $16.29 billion, compared with roughly $1.2 billion the year before, though it posted an $80.75 billion net loss, mostly from non-cash accounting charges.
Anthropic is reportedly preparing a Nasdaq listing around mid-November, but investors now expect a valuation of $1 trillion to $1.5 trillion, below the $2 trillion mentioned in recent months.
The market backdrop is tough. The Nasdaq took its biggest hit in about 19 months last week, and voters pushed back on AI in the November 3 elections, with local data centre measures rejected in 40 of 41 races.
The company, led by CEO Dario Amodei, is best known for its Claude AI models, which are mainly sold to businesses.
Indian Entrepreneur@indianentrepreneur
Bindi